Thu, 28 Aug 2008 03:43:59 GMT

Novartis announced that Glivec (imatinib) has been granted priority review status by the US Food and Drug Administration (FDA) as the first therapy to be reviewed for use after surgery in kit-positive gastrointestinal stromal tumours (GIST). FDA priority review status is granted to therapies that could potentially fill a currently unmet medical need and accelerates the standard review timing ...

Wed, 20 Aug 2008 11:57:16 GMT

This article is provided to FT.com readers by Pharmawire —a news service focused on providing insight into the most price sensitive issues in the global pharmaceutical market.

Tue, 19 Aug 2008 23:01:35 GMT

TUESDAY, Aug. 19 (HealthDay News) -- Zoledronic acid prevents bone loss in breast cancer patients undergoing endocrine therapy and improves bone mineral density after treatment, according to an Austrian study.